6-Month, Multicenter, Randomized, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin Antihyperglycemic Drugs
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Jul 2018
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EDITION AP
- Sponsors Sanofi
- 27 Jun 2018 Planned End Date changed from 6 Aug 2018 to 1 Aug 2018.
- 27 Jun 2018 Planned primary completion date changed from 6 Aug 2018 to 1 Aug 2018.
- 27 Jun 2018 Status changed from recruiting to active, no longer recruiting.